palsonify

Generic: paltusotine

palsonify: developed by 1 company · 2 FDA decisions. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
Crinetics Pharmaceuticals, Inc. (CRNX)Approved

FDA Decisions

PDUFAacromegaly(CRNX)
FDA_MeetingNew Drug Application submitted to the FDA for paltusotine for treatment and long-term maintenance therapy of acromegaly.(CRNX)

Frequently asked questions

Who is developing palsonify?

palsonify is being developed by Crinetics Pharmaceuticals, Inc..

What is palsonify's latest FDA decision?

The most recent tracked FDA decision for palsonify is PDUFA for acromegaly, dated September 25, 2025.

Get deeper analysis on palsonify

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    palsonify — Drug Pipeline, Trials & FDA Status | BioSniper